Angela Märten Selected Research

Angela Märten Research Topics

Disease

28	Neoplasms (Cancer) 01/2022 - 12/2002
23	Pancreatic Neoplasms (Pancreatic Cancer) 07/2015 - 12/2003
17	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 10/2014
11	Adenocarcinoma 02/2010 - 12/2003
4	Renal Cell Carcinoma (Grawitz Tumor) 02/2006 - 12/2002
3	Brain Neoplasms (Brain Tumor) 12/2021 - 01/2015
3	Disease Progression 07/2021 - 02/2006
2	Exanthema (Rash) 01/2018 - 08/2014
1	Body Weight (Weight, Body) 01/2019
1	Drug-Related Side Effects and Adverse Reactions 01/2019
1	Chronic Disease (Chronic Diseases) 01/2019
1	Cough 01/2018
1	Diarrhea 01/2018
1	Dyspnea (Shortness of Breath) 01/2018
1	Lung Neoplasms (Lung Cancer) 01/2018
1	Pain (Aches) 01/2018
1	Acne Vulgaris 01/2018
1	Stomatitis 01/2018
1	Adenocarcinoma of Lung 01/2018
1	Neoplasm Metastasis (Metastasis) 01/2015
1	Multiple Myeloma 06/2010
1	Cachexia 11/2009
1	Hypoxia (Hypoxemia) 11/2008
1	Colonic Neoplasms (Colon Cancer) 02/2008
1	Pathologic Neovascularization 01/2008
1	Liver Neoplasms (Liver Cancer) 05/2006
1	Hepatocellular Carcinoma (Hepatoma) 04/2006
1	Leukemia 01/2004
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2004
1	Hypersensitivity (Allergy) 03/2003

Drug/Important Bio-Agent (IBA)

16	AfatinibIBA 01/2022 - 10/2014
10	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2015
7	Interferon-alpha (Interferon Alfa)IBA 09/2008 - 08/2004
6	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2015
5	Gemcitabine FDA Link 01/2018 - 08/2004
5	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2015 - 01/2010
5	AntigensIBA 05/2007 - 01/2004
4	osimertinibIBA 12/2021 - 11/2018
3	Gefitinib (Iressa)FDA Link 06/2019 - 10/2014
3	Pharmaceutical PreparationsIBA 07/2015 - 05/2007
3	Capecitabine (Xeloda)FDA Link 07/2015 - 01/2010
3	Fluorouracil (Carac)FDA LinkGeneric 04/2012 - 11/2006
3	InterferonsIBA 04/2012 - 01/2008
3	Proteins (Proteins, Gene)FDA Link 02/2010 - 01/2004
3	Telomerase (Telomerase Reverse Transcriptase)IBA 02/2006 - 01/2004
2	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 11/2006
2	Biomarkers (Surrogate Marker)IBA 08/2014 - 04/2012
2	LigandsIBA 04/2012 - 06/2010
2	Complement C3b (C3bi)IBA 02/2010 - 01/2006
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2008 - 01/2008
2	Subfamily B ATP Binding Cassette TransporterIBA 05/2008 - 01/2008
2	Peptides (Polypeptides)IBA 01/2008 - 01/2004
2	AntibodiesIBA 11/2006 - 05/2006
1	PlatinumIBA 01/2019
1	thiamine triphosphorate (TTP)IBA 01/2019
1	Biological ProductsIBA 07/2015
1	Cytostatic AgentsIBA 05/2013
1	AutoantibodiesIBA 02/2010
1	Complement System Proteins (Complement)IBA 02/2010
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2009
1	Bortezomib (Velcade)FDA Link 11/2008
1	Proteasome InhibitorsIBA 11/2008
1	Proteasome Endopeptidase Complex (Proteasome)IBA 11/2008
1	Small Interfering RNA (siRNA)IBA 02/2008
1	LipidsIBA 02/2008
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2008
1	Coloring Agents (Dyes)IBA 01/2008
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2008
1	Messenger RNA (mRNA)IBA 01/2008
1	reversin 121IBA 01/2008
1	Diphosphonates (Bisphosphonates)IBA 05/2007
1	Zoledronic Acid (Zometa)FDA Link 05/2007
1	micaIBA 11/2006
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 04/2006
1	Fetal Proteins (Fetoprotein)IBA 04/2006
1	CytokinesIBA 04/2006
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2006
1	HLA Antigens (Human Leukocyte Antigens)IBA 02/2006
1	Interleukin-10 (Interleukin 10)IBA 11/2004
1	Antineoplastic Agents (Antineoplastics)IBA 12/2003
1	RNA (Ribonucleic Acid)IBA 12/2003
1	Interferon-gamma (Interferon, gamma)IBA 03/2003
1	VaccinesIBA 12/2002

Therapy/Procedure

16	Drug Therapy (Chemotherapy) 01/2019 - 08/2004
11	Therapeutics 01/2019 - 01/2004
5	Time-to-Treatment 09/2019 - 01/2015
5	Immunotherapy 06/2008 - 04/2003
4	Chemoradiotherapy 09/2008 - 11/2006
2	Radiotherapy 07/2009 - 05/2008
1	Drug Tapering 01/2019
1	Parenteral Nutrition 11/2009
1	Hematopoietic Stem Cell Transplantation 04/2003
1	Transplantation 04/2003
1	Bone Marrow Purging 04/2003
1	Aftercare (After-Treatment) 03/2003